Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|October 3, 2017
Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaNeda Hashemi-Sadraei, Olumide B Gbolahan, Hai Salfity, et al.
Gastrointestinal Cancer Research : GCR|May 23, 2009
A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or HigherUsman Shah, Bert O'Neil, Jill Allen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 13, 2018
Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 TrialAllen Cohn, Michael A Morse, Bert O'Neil, et al.
Investigational New Drugs|October 16, 2009
Phase I trial of vinflunine and pemetrexed in refractory solid tumorsHanna K Sanoff, Janine Davies, Christine Walko, et al.
Gastrointestinal Endoscopy|September 18, 2018
Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancerJohn M DeWitt, Kumar Sandrasegaran, Bert O'Neil, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2023
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)Walid L Shaib, Rupji Manali, Yuan Liu, et al.
Future Oncology (London, England)|February 16, 2019
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabineMohamad Bassam Sonbol, Daniel H Ahn, David Goldstein, et al.
Medrxiv : the Preprint Server for Health Sciences|April 16, 2025
A Phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/Ref-1 in CancerMark R Kelley, Jun Wan, Sheng Liu, et al.
The Oncologist|February 7, 2024
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular CarcinomaShawn Yu, Menggang Yu, Barry Keane, et al.
The Oncologist|December 22, 2025
A Phase I study targeting the APE1/ref-1 redox signaling protein with APX3330: First clinical agent targeting APE1/ref-1 in CancerMark R Kelley, Jun Wan, Sheng Liu, et al.
Pageof 5